Lymphoma Clinical Trials
1) 2ND line or greater/ SGN35-031: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2) CTMX-M-2029-001 (CytomX) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas.
3) MOR208C310 frontMIND: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate, and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
4)NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.
FOLLICULAR LYMPHOMA Grade 1 to 3a or R/R Marginal Zone Lymphoma (2)
1) INCMOR 0208-301 inMIND: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.
2) NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.
Send UsA Message
The Power of a United Breast Cancer Team: Your Leading Breast Cancer Allies
From diagnosis to treatment and follow-ups, Charleston Oncology, as a part of the Department of Bon Secours St. Francis’ leading multidisciplinary cancer care team, plays a vital role in guiding patients through their breast cancer journey.
Celebrating Strength and Hope: Join Us for the 6th Annual Pink Promenade
Celebrating Strength and Hope: Join Us for the 6th Annual Pink Promenade Mount Pleasant Towne Centre is thrilled to announce our 6th Annual Pink Promenade Breast Cancer Awareness Fundraiser, an event that embodies hope, strength, and resilience. Scheduled for...
Jenny’s Journey Reflects Our Mission
At Charleston Oncology, the mission of healing all people with compassion, faith and excellence resonates through the hallways and translates into every patient interaction.
Myra Walks in a Patient’s Shoes
In the busy corridors of Charleston Oncology on a triple-booked day of patients, a moment of pure human kindness unfolded, illustrating what it truly means to walk in a patient’s shoes.
March is National Colorectal Cancer Awareness Month
March is Colorectal Cancer Awareness Month. This month, Charleston Oncology recognizes the importance of spreading awareness surrounding the disease.
Empowering Health: Charleston Oncology Observes National Cancer Prevention Month
Empowering Health: Charleston Oncology Observes National Cancer Prevention Month Every year in the United States, nearly 1.9 million people (about twice the population of South Dakota) face the life-altering diagnosis of cancer, according to the National Institutes of...
